慢性乙型肝炎治愈新药研究进展

doi:10.3969/j.issn.1672-5069.2019.03.003

Abstract

Zhang Qian, Hu Peng. Highlights in antiviral therapy for chronic hepatitis B[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 313-317.

[1] Lozano R,Naghavi M,Foreman K,et al.Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010:a systematic analysis for the Global Burden of Disease Study 2010. Lancet,2012,380(9859):2095-2128.
[2] Lu FM,Zhuang H.Management of hepatitis B in China. Chin Med J,2009,122(1):3-4.
[3] Lok AS,Zoulim F,Dusheiko G,et al.Hepatitis B cure:From discovery to regulatory approval. Hepatology,2017,66(4):1296-1313.
[4] BJ. The natural history of chronic hepatitis B virus infection. Hepatology,2009,49(5):S45-S55.
[5] Trepo C,Chan HLY,Lok A.Hepatitis B virus infection. Lancet,2014,384(9959):2053-2063.
[6] Yapali S,Talaat N,Lok AS.Management of hepatitis B:Our practice and how it relates to the guidelines. Clin Gastroenterol H,2014,12(1):16-26.
[7] Hu P,Dou XG,Jiang JN,et al.Increased and sustained HBsAg loss in HBeAg positive CHB patients switched from NUC to Peg-IFN alfa-2a:A randomised open label trial(NEW SWITCH study). Hepatology,2016,64:36a-37a.
[8] Qiu K,Liu B,Li SY,et al.Systematic review with meta-analysis:combination treatment of regimens based on pegylated interferon for chronic hepatitis B focusing on hepatitis B surface antigen clearance. Aliment Pharm Ther,2018,47(10):1340-1348.
[9] Heiner Wedemeyer KS,Bogomolov PO,Voronkova NV, et al.Interim results of a multicentre,open label phase 2 clinical trial (MYR203) to assess safety and effcacy of myrcludex B in combination with peg-interferon alpha 2a in patients with chronic HBV/HDV co-infection. Hepatology,2018,68:11A.
[10] Lucifora J,Xia YC,Reisinger F,et al.Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA. Science, 2014,343(6176):1221-1228.
[11] Xia YC,Stadler D,Lucifora J,et al.Interferon-gamma and tumor necrosis factor-alpha produced by T cells reduce the HBV persistence form,cccDNA,without cytolysis. Gastroenterology,2016,150(1):194-205.
[12] Xia YC,Lucifora J,Reisinger F,et al.VIROLOGY response to comment on “specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA”. Science,2014,344(6189):142-144.
[13] Ramanan V,Shlomai A,Cox DBT,et al.CRISPR/Cas9 cleavage of viral DNA efficiently suppresses hepatitis B virus. Sci Rep-Uk,2015,5:132-136.
[14] Seeger C,Sohn JA.Complete sof CRISPR/Cas9-induced mutations on HBV cccDNA. Mol Ther,2016,24(7):1258-1266.
[15] Tropberger P,Mercier A,Robinson M,et al.Mapping of histone modifications in episomal HBV cccDNA uncovers an unusual chromatin organization amenable to epigenetic manipulation. Proc Natl Acad Sci USA,2015,112(42):E5715-E5724.
[16] Murphy CM,Xu YP,Li F,et al.Hepatitis B virus X protein promotes degradation of SMC5/6 to enhance HBV replication. Cell Rep,2016,16(11):2846-2854.
[17] Streinu-Cercel A,Gane E,Cheng W,et al.A phase 2a study evaluating the multi-dose activity of ARB-1467 in HBeAg positive and negative virally suppressed subjects with hepatitis B. J Hepatol,2017,66(1):S688-S689.
[18] Wooddell CI,Yuen MF,Chan HLY,et al.RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg. Sci Transl Med,2017,9(409):182-187.
[19] Ganeea EJ. First results with RNA interference(RNAi) in chronic hepatitis B(CHB) using ARO-HBV. Hepatology,2018,68:LB-25.
[20] Fabien Zoulim JY,Vandenbossche JJ,Moscalu I,et al.Safety,pharmacokinetics and antiviral activity of a novel hepatitis B virus (HBV) capsid assembly modulator,JNJ-56136379, in patients with chronic hepatitis B (CHB). Hepatology,2018,68:47A-48A.
[21] Man-Fung Yuen KA,Gane EJ,Schwabe C,et al. Final results of a phase 1b 28-day study of ABI-H0731,a novel core inhibitor,in noncirrhotic viremic subjects with chronic hepatitis B. Hepatology,2018,68:46A-47A.
[22] Yuen MF,Kim DJ,Weilert F,et al.Nvr 3-778,a first-in-class HBVcore inhibitor,alone and in combination with peg-interferon (Pegifn),in treatment-naive Hbeag-positive patients:Early reductions in HBV DNA and HbeAg. J Hepatol,2016,64:S210-S211.
[23] Schwabe C.A phase 1 single and multiple dose-escalating study to evaluate the safety,tolerability,pharmacokinetics and effect of ARO-AAT on serum alpha-1 antitrypsin levels in normal adult volunteers. J Hepatol,2016,62:195-198.
[24] Al-Mahtab M,Bazinet M,Vaillant A.Safety and efficacy of nucleic acid polymers in monotherapy and combined with immunotherapy in treatment-naive Bangladeshi patients with HBeAg+ chronic hepatitis B infection. PLoS One,2016,11(6):e0156667.
[25] Bazinet M,Pantea V,Cebotarescu V,et al.Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF):a non-randomised,open-label,phase 2 trial. Lancet Gastroenterol Hepatol,2017,2(12):877-889.
[26] Ko C,Michler T,Protzer U.Novel viral and host targets to cure hepatitis B. Curr Opin Virol,2017,24:38-45.
[27] Xu DZ,Zhao K,Guo LM,et al.A randomized controlled phase IIb trial of antigen-antibody immunogenic complex therapeutic vaccine in chronic hepatitis B patients. PLoS One,2008,3(7):e2565.
[28] Xu DZ,Wang XY,Shen XL,et al.Results of a phase III clinical trial with an HBsAg-HBIG immunogenic complex therapeutic vaccine for chronic hepatitis B patients:experiences and findings. J Hepatol,2013,59(3):450-456.
[29] Wang XY,Yao X,Wan YM,et al.Responses to multiple injections with alum alone compared to injections with alum adsorbed to proteins in mice. Immunol Lett,2013,149(1-2):88-92.
[30] Lok AS,Pan CQ,Han SHB,et al.Randomized phase II study of GS-4774 as a therapeutic vaccine in virally suppressed patients with chronic hepatitis B. J Hepatol,2016,65(3):509-516.
[31] Emery JS,Feld JJ.Treatment of hepatitis B virus with combination therapy now and in the future. Best Pract Res Cl Ga,2017,31(3):347-355.
[32] Lobaina Y,Michel ML.Chronic hepatitis B:Immunological profile and current therapeutic vaccines in clinical trials. Vaccine,2017,35(18):2308-2314.
[33] Agarwal K,Ahn SH,Elkhashab M,et al.Safety and efficacy of vesatolimod(GS-9620) in patients with chronic hepatitis B who are not currently on antiviral treatment. J Viral Hepat,2018,25(11):1331-1340.
[34] Man-Fung Yuen ME,Chen CY,Chen YF,et al. Inarigivir demonstrates potent dose dependent anti-viral activity in HBV treatment-naive patients:Role of HBeAg status and baseline HBsAg in anti-viral response. Hepatology,2018,68:48A.
[35] Janssen HLA,Brunetto MR,Kim YJ,et al.Safety,efficacy and pharmacodynamics of vesatolimod(GS-9620) in virally suppressed patients with chronic hepatitis B. J Hepatol,2018,68(3):431-440.
[36] Gane E,Gaggar A,Nguyen AH,et al.A phase1 study evaluating anti-PD-1 treatment with or without GS-4774 in HBeAg negative chronic hepatitis B patients. J Hepatol,2017,66(1):S26-S27.
[37] Mak LY,Seto WK,Fung J,et al.Novel developments of hepatitis B:treatment goals,agents and monitoring tools. Expert Rev Clin Phar,2019,12(2):109-120.

Highlights in antiviral therapy for chronic hepatitis B

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	chronic hepatitis B Zhu Lingyun, Zhang Maohai Cui Shasha, et al.. Serum IL-12 and IL-18 levels as well as peripheral blood mononuclear cell FOXp3 in patients with [J]. Journal of Practical Hepatology, 2019, 22(6): 816-819.
[2]	Shi Yingying, Wang Yuanxi.. Impact of combination telbivudine and adefovir dipivoxil on renal functions in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 820-823.
[3]	Min Feng, Huang Wenqi, Wu Weibing, et al.. Implications of serum adipocytokine levels in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 824-827.
[4]	patients with chronic hepatitis B Zhang Yingming, Shen Shuang, Tian Fei, et al.. Prediction of response to peginterferon alfa-2a by blood IFNL4 and IL-28B gene polymorphisms in [J]. Journal of Practical Hepatology, 2019, 22(6): 828-831.
[5]	chronic hepatitis B virus carriers Wu Haiyi, Chen Jianxin.. Diagnostic efficacy of four non-invasive diagnostic models in evaluating significant liver fibrosis in [J]. Journal of Practical Hepatology, 2019, 22(6): 832-835.
[6]	Ma Liying, Shen Lijuan.. Efficacy and safety of tenofovir in the treatment of pregnant women with high HBV DNA loads [J]. Journal of Practical Hepatology, 2019, 22(6): 836-839.
[7]	Li Chuanjie, Xu Jing, Wang Liangliang, et al.. Changes of serum HBsAg levels in patients with chronic hepatitis B receiving entecavir treatment [J]. Journal of Practical Hepatology, 2019, 22(6): 928-929.
[8]	Du Keye, Yang Dongliang, Liu Jia. Regulatory T cells in hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 613-616.
[9]	Liao Guichan, Peng Jie, Zhang Xiaoyong. Roles of hepatocytes in intrinsic innate immunity in control of hepatits B virus infection [J]. Journal of Practical Hepatology, 2019, 22(5): 617-619.
[10]	Zhao Xieshan, Wu Chunrong, Wang Chunfeng, et al. Preliminary study on the efficacy of combination of tenofovir and Anluo Huaxian pill in the treatment of patients with HBeAg-negative chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 644-647.
[11]	Tu Jiexia, Wang An’na, Liao Ruoxi. Comparative study of interferon alpha -2b and peginterferon alpha -2a in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 648-651.
[12]	Gao Wei, Hou Yong. Diagnostic efficacy of hepatic fibrosis by liver stiffness measurement in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 652-655.
[13]	Zhu Yucheng, Yan Jiawei, Sun Jingkun, et al. Serum diamine oxidase level in patients with hepatitis B-induced acute-on-chronic liver failure [J]. Journal of Practical Hepatology, 2019, 22(5): 672-675.
[14]	Zhang Mei, Shi Xiuying, Li Linjuan, et al. Hepatic expression of interferon inducible protein -10 in patients with hepatitis B liver cirrhosis and hepatogenic diabetes mellitus [J]. Journal of Practical Hepatology, 2019, 22(5): 688-691.
[15]	Han Meiling, Chen Ping. Antiviral therapy in patients with liver cirrhosis and thrombocytopenia [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 466-469.